Blenrep (belantamab mafadotin) for multiple myeloma — Dr. Jesus Berdeja | MCRT Webcast August 22

Blenrep (belantamab mafadotin) for multiple myeloma — Dr. Jesus Berdeja | MCRT Webcast August 22

The promise of belantamab mafodotin for the treatment of multiple myelomaПодробнее

The promise of belantamab mafodotin for the treatment of multiple myeloma

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myelomaПодробнее

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma

Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple MyelomaПодробнее

Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple Myeloma

BLENREP (belantamab mafodotin-blmf) Mechanism of Action in Multiple MyelomaПодробнее

BLENREP (belantamab mafodotin-blmf) Mechanism of Action in Multiple Myeloma

Know Your Myeloma Immunotherapy: Antibody Drug Conjugates with Dr. Jesus BerdejaПодробнее

Know Your Myeloma Immunotherapy: Antibody Drug Conjugates with Dr. Jesus Berdeja

All About BLENREP (Belantamab Mafodotin-blmf)Подробнее

All About BLENREP (Belantamab Mafodotin-blmf)

MCRT San Diego 2020: Jesús Berdeja Presentation - ImmunotherapiesПодробнее

MCRT San Diego 2020: Jesús Berdeja Presentation - Immunotherapies

Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple MyelomaПодробнее

Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple Myeloma

Treatment combinations being explored with belantamab mafodotin in multiple myelomaПодробнее

Treatment combinations being explored with belantamab mafodotin in multiple myeloma

Dr. Berdeja on Treatment of Patients With Newly Diagnosed MyelomaПодробнее

Dr. Berdeja on Treatment of Patients With Newly Diagnosed Myeloma

DREAMM-2: Belantamab mafodotin for R/R myelomaПодробнее

DREAMM-2: Belantamab mafodotin for R/R myeloma

Dr. Berdeja on Maintenance Therapy in Multiple MyelomaПодробнее

Dr. Berdeja on Maintenance Therapy in Multiple Myeloma

Managing belantamab mafodotin-associated corneal adverse events in multiple myelomaПодробнее

Managing belantamab mafodotin-associated corneal adverse events in multiple myeloma

Dr. Berdeja on Updated Data With bb21217 in Multiple MyelomaПодробнее

Dr. Berdeja on Updated Data With bb21217 in Multiple Myeloma

Jesus Berdeja, MD, shares design and outcomes of the CARTITUDE-1 trial in multiple myeloma patientsПодробнее

Jesus Berdeja, MD, shares design and outcomes of the CARTITUDE-1 trial in multiple myeloma patients

Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trialsПодробнее

Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trials

The potential role of belantamab mafodotin in multiple myelomaПодробнее

The potential role of belantamab mafodotin in multiple myeloma